Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/53926
Title: | Regulatory sciences and translational pharmacogenetics : amitriptyline as a case in point |
Authors: | Mifsud Buhagiar, Luana Micallef, Benjamin Borg, John-Joseph Vella, Helen Serracino-Inglott, Anthony LaFerla, Godfrey |
Keywords: | Pharmaceutical chemistry Drug development -- Safety measures Drug approval Labels Pharmacogenetics |
Issue Date: | 2019 |
Publisher: | De Gruyter |
Citation: | Mifsud, L. B., Micallef, B., Borg, J. J., Vella, H., Serracino, A. I., & LaFerla, G. (2019). Regulatory sciences and translational pharmacogenetics: amitriptyline as a case in point. Drug Metabolism and Personalized Therapy, 34(2). |
Abstract: | Regulatory developments and clinical implementation, or the lack thereof, are primary clinchers, in the enduring endeavors to realize the translational quality of pharmacogenetics. Here, we present the case of amitriptyline, an established drug with pharmacogenetic implications. The integration of pharmacogenetic information in the official product literature and throughout the evaluation of safety concerns is considered. In our opinion, apart from emboldening genomic research in drug development and the valid pursuit towards global harmonization in the field, it is rational to look into the applicability of the data we have today. |
URI: | https://www.um.edu.mt/library/oar/handle/123456789/53926 |
Appears in Collections: | Scholarly Works - FacM&SPha |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Regulatory _sciences _and _translational_pharmacogenetics_amitriptyline_as_a_case_in_point.pdf Restricted Access | 83.02 kB | Adobe PDF | View/Open Request a copy |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.